BioPoint Inc

01/30/2026

Eli Lilly announced a $3.5B injectable and device manufacturing plant in Pennsylvania, completing its plan for four new U.S. facilities focused on next-generation therapies including weight-loss injectables. This expansion is part of a broader effort to boost domestic production and create hundreds of new jobs. https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa

And then there were four. | On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding out the quartet of plants it promised during its “Lilly in America” investment announcement last year.

01/29/2026

Roche is pushing to become a top-three player in the obesity drug market by advancing a broad weight-loss pipeline to challenge leaders Novo Nordisk and Eli Lilly. The strategy includes promising clinical data and strategic deals aimed at diversifying its obesity treatment offerings. https://www.biospace.com/business/roche-plans-to-go-toe-to-toe-with-novo-lilly-in-obesity

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a presentation of the company's full-year 2025 earnings.

01/28/2026

The FDA has approved Johnson & Johnson’s Darzalex Faspro as part of a four-drug frontline regimen for newly diagnosed multiple myeloma patients who can’t undergo stem cell transplant. This marks another expanded indication for the therapy and strengthens its role in first-line treatment. https://www.biospace.com/fda/j-js-darzalex-faspro-notches-another-multiple-myeloma-indication-pushing-into-frontline

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.

01/27/2026

Sarepta’s gene therapy Elevidys for Duchenne muscular dystrophy significantly slowed disease progression and sustained motor function benefits three years after treatment in a Phase III trial. The positive long-term data come after safety concerns and patient deaths in 2025, offering renewed optimism for the therapy. https://www.biospace.com/drug-development/sareptas-dmd-gene-therapy-staves-off-disease-three-years-after-treatment

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

01/26/2026

Corcept’s ovarian cancer drug just showed strong Phase III efficacy, setting it up as a serious challenger to Merck and AbbVie. This breakthrough could shift the competitive landscape in ovarian cancer treatment. https://www.biospace.com/drug-development/corcepts-ovarian-cancer-drug-hits-robust-efficacy-in-phase-iii-setting-up-challenge-to-merck-abbvie

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.

01/23/2026

The House is voting on a $1.2 trillion spending bill that includes renewing the FDA’s Rare Pediatric Disease Priority Review Voucher program and reforms for pharmacy benefit managers to increase pricing transparency. If passed, the bill would move to the Senate next for consideration. https://www.biospace.com/policy/rare-pediatric-disease-vouchers-pbm-reform-up-for-vote-in-house

The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.

01/22/2026

Lexicon Pharmaceuticals received FDA agreement to move its non-opioid pain pill pilavapadin into Phase III testing, advancing a potential treatment for diabetic peripheral neuropathic pain. This step opens the door to what analysts see as a market opportunity worth over $1 billion. https://www.biospace.com/drug-development/lexicon-opens-path-to-1b-opportunity-as-fda-greenlights-phase-iii-for-non-opioid-pill

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.

01/21/2026

Johnson & Johnson reported strong 2025 results and is targeting about $100 billion in sales for 2026, signaling growth across its portfolio even after Stelara lost patent exclusivity. The company says it has effectively moved past the Stelara patent cliff with other drugs picking up momentum. https://www.biospace.com/business/j-j-aims-for-100b-in-sales-puts-stelara-patent-cliff-in-the-rearview-mirror

Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while standing fast on its talc lawsuit and tariffs.

01/19/2026

Today we honor the legacy of Dr. Martin Luther King Jr., whose words and actions continue to inspire service, integrity, and unity. His commitment to dignity and respect for all remains a timeless guide for leadership and community.



Image Credit: Duke University Archives. Durham, North Carolina, USA

01/19/2026

Novo Nordisk’s new oral Wegovy has enrolled over 3,000 patients in its first week on the market, signaling strong early demand. The launch boosts the company’s position in the obesity treatment space. https://www.biospace.com/business/novo-rises-as-oral-wegovy-reaches-over-3-000-patients-in-first-week-of-launch

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.

01/16/2026

AbbVie’s Skyrizi was the top TV drug ad spender for the full year again, leading annual pharmaceutical TV ad spending with hundreds of millions invested. Johnson & Johnson’s Tremfya was a close challenger, frequently trading monthly spots but finishing just behind Skyrizi in total spend. https://www.fiercepharma.com/marketing/abbvies-skyrizi-takes-full-year-tv-ad-spending-crown-yet-again-jjs-tremfya-hot-pursuit

For the fourth year running—and the third in a row for | For the fourth year running—and the third in a row for Skyrizi specifically—an AbbVie immunology med has claimed the top spot in the full-year TV drug ad spending rankings.

01/15/2026

The FDA has asked Novo Nordisk and Eli Lilly to remove suicide-related warnings from their GLP-1 weight-loss drug labels after a review found no evidence these medications increase risk of suicidal thoughts or behavior. https://www.biospace.com/fda/fda-asks-novo-lilly-to-remove-suicide-warnings-from-glp-1-weight-loss-products

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.